Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Bolsa de valores de Sao Paulo  >  Hypermarcas SA    HYPE3   BRHYPEACNOR0

End-of-day quote. End-of-day quote  - 09/20
33.67 BRL   +0.42%
08/01 HYPERMARCAS : Notice to the Market
06/26 HYPERMARCAS SA : Capital return instalment
04/24 J&J, Takeda among interested in Brazil's Hypermarcas, sources say
News SummaryMost relevantAll newsSector newsTweets

Hypermarcas SA : Brazil's Hypermarcas returns to profit as debt costs sink

share with twitter share with LinkedIn share with facebook
share via e-mail
11/10/2012 | 04:03pm CEST

Hypermarcas SA, Brazil's largest diversified drugmaker, returned to profit in the third quarter as revenue grew slightly above expectations and debt-servicing and currency hedging costs tumbled from the year-earlier period.

The results were the latest showing that a year-long slowdown in the consumer goods industry is finally easing, with producers of cosmetics, generic drugs and household goods such as Hypermarcas likely to benefit most from Brazil's improving growth trends. Hypermarcas had lost money for two of the past three quarters.

Surging pharmaceutical sales and the integration of acquisitions helped the São Paulo-based producer of Engov hangover pills and Bozzano shaving cream post net income of 68.38 million reais ($33.4 million) in the third quarter, according to a securities filing late on Friday. The result compared with a loss of 190.5 million reais a year earlier.

Third-quarter profit beat the 53 million reais estimate in a Reuters poll of analysts. Management will discuss third-quarter earnings in a conference call with investors early on Monday.

Chief Executive Claudio Bergamo's efforts to streamline operations has restored profitability after a spree of acquisitions in the past four years boosted debt and made Hypermarcas too exposed to an economic slowdown. Bergamo picked pharmaceutical goods and beauty care as the firm's focus, shunning the slower-growing foods and household goods units.

In a separate statement released late on Friday, Management also set an estimate of earnings before interest, tax, depreciation of around 950 million reais for next year, up from guidance of at least 850 million reais in the indicator, known as EBITDA, for this year. EBITDA is a measure of a company's ability to generate profits from its core business.

Lower debt and stronger cash flow generation, coupled with a stable currency, helped Hypermarcas post a net financial shortfall of 54.9 million reais, compared with a deficit of 331.8 million reais a year earlier. The net financial result line is calculated by the difference between debt-servicing and currency hedging expenses and non-operating income, such as gains from financial investments.

Revenue jumped to 992.9 million reais from 832.8 million reais a year earlier, a gain of 19 percent on a year-on-year basis, the company said. Sales of pharmaceutical products, which accounted for about 54 percent of the company's net revenue in the quarter, soared 39 percent, while those of beauty care goods rose 2.2 percent on a year-on-year basis.

The Reuters poll had predicted revenue at 987 million reais for the third quarter.

EBITDA almost quadrupled to 226.6 million reais last quarter from 66.3 million reais in the third quarter of 2011. The EBITDA margin, or how much operating profit was generated from sales, soared to 23 percent from 7.9 percent a year earlier.

EBITDA was expected to come in at 209 million reais in the Reuters poll, below the number reported by the company.

Shares of Hypermarcas, which shed 2.1 percent on Friday and closed the session at 15.32 reais, are up 80 percent so far this year.

($1 = 2.05 Brazilian reais)

(Reporting by Guillermo Parra-Bernal and Vivian Pereira; Editing by Vicki Allen)

By Guillermo Parra-Bernal and Vivian Pereira

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on HYPERMARCAS SA
08/01 HYPERMARCAS : Notice to the Market
06/26 HYPERMARCAS SA : Capital return instalment
04/24 J&J, Takeda among interested in Brazil's Hypermarcas, sources say
04/20 HYPERMARCAS : Notice to Shareholders - Dividend Payment
04/20 HYPERMARCAS SA : ex-dividend day for final dividend
03/09 HYPERMARCAS : Notice to Shareholders - Shareholders' Ordinary and Extraordinary ..
03/07 HYPERMARCAS : Notice to the Market - Corporate Events Calendar Update
02/28 HYPERMARCAS : Notice to Shareholders - Dividend Distribution
02/18 HYPERMARCAS : Material Fact - Guidance
02/16 HYPERMARCAS SA : ex-dividend day for interim dividend
More news
News from SeekingAlpha
09/11 In Healthcare Sector GlaxoSmithKline Remains Top Broker Pick For Gains In Sep..
08/09 GlaxoSmithKline Is Broker Pick As Top Dog For Healthcare Sector Gains In Augu..
07/01 Healthcare Has GlaxoSmithKline As Top Dog By Gains In June
04/18 Healthcare Dogs See Medical Care Tops By Yield But Big Pharma Tops By Gains F..
03/30 COTY : A Stable Business With Expanding Cash Flow Is A Beautiful Thing
Financials ( BRL)
Sales 2017 3 597 M
EBIT 2017 1 162 M
Net income 2017 889 M
Finance 2017 984 M
Yield 2017 3,47%
P/E ratio 2017 23,74
P/E ratio 2018 20,17
EV / Sales 2017 5,62x
EV / Sales 2018 5,07x
Capitalization 21 199 M
Duration : Period :
Hypermarcas SA Technical Analysis Chart | HYPE3 | BRHYPEACNOR0 | 4-Traders
Technical analysis trends HYPERMARCAS SA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 30,9  BRL
Spread / Average Target -7,7%
EPS Revisions
Claudio Bergamo dos Santos Chief Executive Officer & Director
João Alves de Queiroz Filho Chairman
Luiz Eduardo Violland Chief Operating Officer & Director
Breno Toledo Pires de Oliveira Chief Financial & Investor Relations Officer
Esteban Malpica Fomperosa Director
Sector and Competitors